SCHEMBL4939872

SCHEMBL4939872

CCOC(=O)c1ccccc1-c1cn2ccsc2n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
HPGD P15428 3/20 0.48
KDM4E B2RXH2 2/20 0.48
HSD17B10 Q99714 2/20 0.48
TSHR P16473 2/20 0.47
CYP19A1 P11511 1/20 0.46
GAA P10253 2/20 0.46
LMNA P02545 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
POLB P06746 1/20 0.45
ALDH1A1 P00352 2/20 0.44
RECQL P46063 1/20 0.44
TP53 P04637 7/20 0.44
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
NFKB1 P19838 2/20 0.44
NFKB2 Q00653 2/20 0.44
RELA Q04206 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4743514 0.81 RAB9A (0.54) MAPTSMN1; SMN2HPGDKDM4EHSD17B10
SCHEMBL12970535 0.78 SMN1; SMN2 (0.59) MAPTSMN1; SMN2HPGDKDM4EHSD17B10
SCHEMBL1572425 0.75 ALDH1A1 (0.55) MAPTSMN1; SMN2HPGDKDM4EHSD17B10
SCHEMBL3637351 0.75 CYP19A1 (0.71) MAPTSMN1; SMN2HPGDKDM4EHSD17B10
SCHEMBL4741066 0.74 KMT2A (0.57) MAPTSMN1; SMN2HPGDKDM4EHSD17B10
SCHEMBL26643058 0.73 JMJD6 (0.56) MAPTSMN1; SMN2HPGDHSD17B10TSHR
SCHEMBL29617021 0.72 TSHR (0.80) MAPTKDM4EHSD17B10TSHRLMNA
SCHEMBL3683272 0.72 TSHR (0.80) MAPTKDM4EHSD17B10TSHRLMNA
SCHEMBL11831065 0.71 SMN1; SMN2 (0.56) MAPTSMN1; SMN2HPGDKDM4EHSD17B10
SCHEMBL29740241 0.71 TP53 (0.54) MAPTSMN1; SMN2HPGDHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080249130-A1 Gut microsomal triglyceride transport protein inhibitors SIRTRIS PHARMACEUTICALS, INC. (US) 2008-10-09 US disclosed
US-20080249130-A1 Gut microsomal triglyceride transport protein inhibitors SIRTRIS PHARMACEUTICALS, INC. (US) 2008-10-09 US disclosed
US-20080249130-A1 Gut microsomal triglyceride transport protein inhibitors SIRTRIS PHARMACEUTICALS, INC. (US) 2008-10-09 US disclosed
WO-2008100423-A1 GUT MICROSOMAL TRIGLYCERIDE TRANSPORT PROTEIN INHIBITORS SIRTRIS PHARMACEUTICALS, INC. (US) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249130-A1 Gut microsomal triglyceride transport protein inhibitors MTTP, CETP, FABP2 MAPT 2403/4885SMN1; SMN2 4591/4885HPGD 717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.